Eryaspase (Asparaginase)

Active substance
Eryaspase (Asparaginase)
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Pancreatic cancer
Extended indication
Behandeling van pancreatic adenocarcinoma die gefaald hebben op eerstelijns therapie

1. Product

Proprietary name
Graspa
Manufacturer
ERYtech
Mechanism of action
Enzyme
Route of administration
Intravenous
Therapeutical formulation
Intravenous drip
Budgetting framework
Intermural (MSZ)
Additional comments
Asparagine modulator

2. Registration

Registration route
Centralised (EMA)
Orphan drug
No
Registration phase
Clinical trials
Additional comments
Estimated Primary Completion Date 11-2020 phase III.

3. Therapeutic value

Current treatment options
chemotherapie
Therapeutic value
No judgement
Duration of treatment
Not found
Frequency of administration
1 times every 2 weeks
Dosage per administration
100 U/kg
References
NCT03665441
Additional comments
Eryaspase (Asparaginase) wordt naast chemotherapie gegeven.

4. Expected patient volume per year

References
NKR
Additional comments
In totaal zijn er 1.743 patiënten met stadium III en stadium IV alvleesklierkanker. Gezien de nieuwe behandelopties voor pancreascarcinoom is het nog onduidelijk hoeveel patiënten er in de tweedelijn zullen worden behandeld.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
No
References
AdisInsight
Additional comments
Wel voor andere indicaties onderzocht (onder andere borstkanker), maar geen indicatie-uitbreidingen in de komende 2 jaar verwacht.

9. Other information

There is currently no futher information available.